Clinical

An interim analysis of the KEYNOTE-716 trial of adjuvant pembrolizumab supports its use in the adjuvant setting for patients with resected melanoma.

Among a real-world cohort of patients, switching between infliximab biosimilars was effective and well tolerated, although retention was higher among those who had initially started on the originator product.

Patients who received a diagnosis of small cell lung cancer (SCLC) between 2010 and 2016 had a nearly 2% increase in overall survival vs those who received their diagnosis between 2004 and 2010.

Most patients taking a biologic stayed on the therapy, and most saw decreases in exacerbations, a new study has found.

The findings of this study, which used insurance claims data for patients 2 years and older to determine rates of meningococcal A, C, W, Y vaccine uptake, points to the need for more education, the authors said.

Among patients with severe asthma with low eosinophils untreated with biologics, there is a high burden of disease among those who have suboptimal disease control.

The study included children and adolescents, and it found decreased vertebral height and depth among both groups of patients compared with healthy controls.

The FDA and the CDC’s Advisory Committee on Immunization Practices (ACIP) Wednesday gave positive decisions on an expanded indication for Merck’s pneumococcal 15-valent conjugate vaccine (Vaxneuvance).

Abstracts presented at EULAR 2022 focused on racial differences in gout prevalence and treatment, highlighting racial disparities in recent decades.

Collecting more than 3 decades’ worth of data, researchers determined that none of the identified blood biomarkers are accurate enough to take the place of current diagnostic approaches, either due to lack of data or lack of specificity.

Research supports markers like C-peptide not only for the diagnosis of type 1 diabetes (T1D), but also for patient management.

In this study, Italian investigators evaluated how sacubitril/valsartan (Sac/Val) dose titration among older patients with heart failure with reduced ejection fraction (HFrEF) might affect reverse cardiac remodeling and if the success of up-titration can be predicted.

Three medical experts highlight unmet needs they routinely run into while treating patients with NSCLC.

Joshua Sabari, MD, provides a breakdown of advanced non-small cell lung cancer (NSCLC) and its actionable mutations.

Recent research used incidence and mortality data from the GLOBOCAN 2020 database to gain insight into worldwide patterns of non-Hodgkin lymphoma in 2020.

Two practicing physicians discuss clinical pathways and decision-making tactics used at their respective institutions for RRMM management.

Dr Richter explains which patients would benefit the most from using lenalidomide vs pomalidomide, while Dr Kaufman calls attention to clinical trials that support the use of pomalidomide in RRMM therapy.

Dr Kristin Highland continues the treatment landscape discussion, focusing on systemic sclerosis ILD (SSc-ILD) and clinical trial data that studied therapy options for IPF, PF-ILD, and SSc-ILD.

The panel provides an overview of the treatment landscape for idiopathic pulmonary fibrosis (IPF) and progressing fibrosing ILD (PF-ILD).

Dr Arwen Podesta explains her PDT patient selection process and the factors she considers before treatment.

Dr Podesta calls on her experience using PDTs with patients to describe what successes and challenges are common.

A new report offers novel insights into a very small patient population.

Researchers emphasize the importance of characterizing and recognizing this subtype to identify patients at risk of Kaposi sarcoma.

About 43% of patients experienced complete depletion of B cells after the first round of rituximab, and those patients had greater odds of longer-term success.

A patient’s quick response to cemiplimab (Libtayo) was reversed after the therapy was stopped due to progression of apparent metastatic cutaneous squamous cell carcinoma.